New molecularly targeted therapies for glioblastoma multiforme

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2935-2946

  Polivka, Jiri ^a,b,c   Rohan, Vladimir ^c   Topolcan, Ondrej ^c   Ferda, Ondrej ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF WEST BOHEMIA   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Glioblastoma multiforme; Molecularly targeted therapeutics; Personalised medicine; Review; Tumor biomarkers

Indexed keywords

ANGIOGENESIS INHIBITOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMMUNOMODULATING AGENT; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN INHIBITOR; TEMOZOLOMIDE; TUMOR VACCINE;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR VASCULARIZATION;

EID: 84865689994     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Central Nervous System Cancers. v.1.2010. http://www.nccn.org/ professionals/physician-gls/PDF/cns.pdf. Last accessed 2010.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987-996, 2005.
3. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M and Schackert G: Long-term survival with glioblastoma multiforme. Brain 130(Pt 10): 2596-606, 2007.
4. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. 2011; www.cbtrus.org/ reports/reports.html. Last accessed August 19, 2011.
5. Burger P, Vogel F, Green S and Strike T: Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications. Cancer 56: 1106-1111, 1985.
6. Kleihues P and Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1(1): 44-51, 1999.
7. Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5): 1445-53, 2007.
8. Rich JN and Bigner DD: Development of novel targeted therapies in treatment of malignant glioma. Nature 3: 430-446, 2004.
9. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A and Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147, 1985.
10. James CD, Carlbom E, Nordenskjold M, Collins VP and Cavenee WK: Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci USA 86: 2858-2862,1989.
11. Yin S. and Van Meir EG: p53 pathway alterations in brain tumors. In: Van Meir EG (ed.). CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1. New York: Humana Press (Springer), pp. 283-314, 2009.
12. Stokoe D. and Furnari FB: The PTEN/PI3 kinase pathway in human glioma. In: Van Meir, EG., editor. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. 1. New York: Humana Press (Springer), pp. 315-357, 2009.
13. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE and Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
14. Rao SK, Edwards J, Joshi AD, Siu IM and Riggins GJ: A survey of glioblastoma genomic amplifications and deletions. J Neurooncol 96: 169-179, 2010.
15. The Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
16. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM and Hayes DN: An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17: 98-110, 2010.
17. Frezza C, Tennant DA and Gottlieb E: IDH1 Mutations in gliomas: When an enzyme loses its grip. Cancer Cell 1917: 7-9, 2010.
18. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B and Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009.
19. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW and Aldape K: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522, 2010.
20. Metellus P, Carole C, Mausas de Paula A, Marylin B, Chinot O, Ouafik LH and Figarella-Branger D: Triple-negative low-grade gliomas: A highly agressive tumor with dismal prognosis. Abstract No 64. Neuro Oncol 13(Suppl 3): iii41-iii68, 2011.
21. Aldape KD, Gilbert M, Cahill D, Wang M, Won M, Hegi M, Colman H, Mehta M and Sulman E: Clinical utility of G-CIMP and IDH1 status as dual prognostic markers in glioblastoma. Abstract OM-35. Neuro Oncol 13(Suppl 3): iii76-iii84, 2011.
22. Sulman EP, Cahill DP, Wang M, Won M, Hegi M, Mehta MP, Aldape KD and Gilbert MR: A combined molecular clinical predictor of survival validated with the RTOG-0525 cohort. Abstract OM-30. Neuro Oncol 13(Suppl 3): iii76-iii84, 2011.
23. Juratli TA, Kirsch M, Schackert G and Krex D: IDH mutations and their role in progression of low-grade gliomas. Abstract NO-45. Neuro Oncol 13(Suppl 3): iii45-iii68, 2011.
24. Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A and Kreth FW: IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged post-recurrence survival. Abstract No-74. Neuro Oncol 13(Suppl 3): iii41-iii68, 2011.
25. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
26. Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Pollo B, Bissola L, Silvani A, Bianchessi D, D'Incerti L, Filippini G, Broggi G, Boiardi A and Finocchiaro G: Methylation of O-6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin. Cancer Res 13(9): 2606-2613, 2007.
27. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R: MGMT gene silencing and benefit from temozolamide in glioblastoma. N Engl J Med 352(10): 997-1003, 2005.
28. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN and Aldape KD: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12: 116-121, 2010.
29. van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Idbaih A, Sanson M, Smitt PA and French PJ: A CpG Island hypermethylated phenotype (CIMP) in anaplastic oligodendroglial brain tumors is a better predictor of survival than MGMT methylation. A report of EORTC study 26951. Abstract OM-05. Neuro Oncol 13(Suppl 3): iii76-iii84, 2011.
30. Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, Aherne W, Pearson A, Bell BA, Zacharoulis S and Papadopoulos MC: Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol 13(1): 99-108, 2011.
31. Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, Tarelli E, Howe FA, Bell BA and Papadopoulos MC: Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 54(4): 713-722, 2008.
32. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM and Holland EC: YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12(19): 5698-704, 2006.
33. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC and Hormigo A: Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol 105(3): 607-612, 2011.
34. Sathornsumetree S and Rich J: New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 6(7): 1087-1104, 2006.
35. Pollack IF: Molecularly targeted therapies for childhood gliomas. In: Molecularly Targeted Therapy for Childhood Cancer. Houghton P (ed.), NY, USA: Springer; 2009.
36. Sathornsumetree S, Reardon D, Desjardins A, Quinn J, Vredenburgh J and Rich J: Molecularly targeted therapy for malignant glioma. Cancer 110: 13-24, 2007.
37. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD and Aldape K: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25: 2288-2294, 2007.
38. Lieberman FS, Cloughesy T, Fine H. NABTC Phase I/II trial of ZD-1839 for recurrent malignit gliomas and unresectable meningiomas. J Clin Oncol 22: 1510, 2004.
39. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD and Friedman HS: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22: 133-142, 2004.
40. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crinò L, Brandes AA: Gefitinib in patients with progressive highgrade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96: 1047-1051, 2007.
41. Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E and Abrey LE: A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92: 99-105, 2009.
42. Cloughesy T, Yung A, Vrendenberg J: Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. J Clin Oncol 23: 1507, 2005.
43. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D and Gorlia T: Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J Clin Oncol 27: 1268-1274, 2009.
44. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V and Yung WK: Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90: 89-97, 2008.
45. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS and Reardon DA: Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12: 1300-1310, 2010.
46. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C and Buckner JC: Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26: 5603-5609, 2008.
47. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE 2nd, Marcello J, Norfleet JA, McLendon RE, Sampson JH and Friedman HS: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96: 219-230, 2010.
48. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL and Mischel PS: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024, 2005.
49. Kuhn J, Robins I and Mehta M: ET-05. Tumor sequestration of lapatinib. Neuro Oncol 10: 783, 2008.
50. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L and Eisenhauer E: A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: Clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65: 353-361, 2009.
51. Belda-Iniesta C, Carpeño Jde C, Saenz EC, Gutiérrez M, Perona R and Barón MG: Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther 5: 912-914, 2006.
52. Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D'Hondt L, Strauven T, Chaskis C, In't Veld P, Michotte A and De Greve J: Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 20(9): 1596-1603, 2009.
53. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT and Poulsen HS: Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 12: 508-516, 2010.
54. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin CH, Wiestler OD, Louis DN, von Deimling A and Nistér M: Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor α receptor expression in human malignant gliomas. Cancer Res 56: 164-171, 1996.
55. Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15: 275-286, 2004.
56. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D and van den Bent MJ: Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26: 4659-4665, 2008.
57. Marosi C, Vedadinejad M, Haberler C: Imatinib mesylate in the treatment of patients with recurrent high grade gliomas expressing PDGF-R. J Clin Oncol 24: 1526, 2006.
58. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ and Friedman HS: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23: 9359-9368, 2005.
59. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A and Nikolova Z: Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101: 1995-2004, 2009.
60. Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R and Nikolova Z: Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patiens with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 96: 393-402, 2010.
61. Jaeckle KA, Anderson SK, Kosel M, Sarkaria J, Brown P, Flynn PJ, Buckner JC and Galanis E: NCCTG N0272: Phase II trial of imatinib mesylate; (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. A North Central Cancer Treatment Group study. Abstract OT-16. Neuro Oncol 13(Suppl 3): iii85-iii91, 2011.
62. Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL and Lamar RE: Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the firstline treatment of patients with glioblastoma multiforme. Cancer 116: 3663-3669, 2010.
63. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE and Wen PY: Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 78: 85-90, 2010.
64. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR and Prados MD: Phase II trial of tipifarnib in patients with recurrent malignit glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24: 3651-3656, 2006.
65. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM and Kun LE: Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a pediatric brain tumor consortium study. J Clin Oncol 25: 3137-3143, 2007.
66. Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amistà P, Rotilio A, Licata C and Fiorentino MV: Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a Phase II study. J Clin Oncol 17: 645, 1999.
67. Spence AM, Peterson RA, Scharnhorst JD, Silbergeld DL and Rostomily RC: Phase II study of concurrent continuous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol 70: 91-95, 2004.
68. Fine HA, Kim L, Royce C. Results from Phase II trial of enzastaurin (LY317615) in patiens with recurrent high grade gliomas: J Clin Oncol 23: 1504, 2005.
69. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE and Fine HA: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28: 1168-1174, 2010.
70. Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D and Fine HA: A phase I/II trial of enzastaurin in patiens with recurrent high-grade gliomas. Neuro Oncol 12: 181-189, 2010.
71. Akhavan D, Cloughesy TF and Mischel PS: mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12: 882-889, 2010.
72. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M andWalsh DJ: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23: 5294-5304, 2005.
73. Papeo G, Forte B, Orsini P, Perrera C, Posteri H, Scolaro A and Montagnoli A: Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opin Ther Pat 19: 1377-1400, 2009.
74. Baker MJ, Brem S, Daniels S, Sherman B and Phuphanich S: Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol 59: 239-242, 2002.
75. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr., Zwiebel J and Buckner JC: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol 27: 2052-2058, 2009.
76. Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360, 2004.
77. Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S and Olson JJ: Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 100: 95-103, 2010.
78. Kubicek GJ, Werner-Wasik M, Machtay M, Mallon G, Myers T, Ramirez M, Andrews D, Curran WJ Jr. and Dicker AP: Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 74: 433-439, 2009.
79. Chi A, Norden AD, Wen PY: Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 7(11): 1537-1560, 2007.
80. Norden AD, Drappatz J and Wen PY: Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7(12): 1152-1160, 2008.
81. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, Broggi G and Boiardi A: Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 62(3): 297-303, 2003.
82. Nam DH, Park K, Suh YL and Kim JH: Expression of VEGF and brain-specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 11 (7): 863-869, 2004.
83. Beal K, Abrey LE and Gutin PH: Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 6: 2, 2011.
84. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30): 4722-4729, 2007.
85. Desjardins A, Vredenburgh JJ, Reardon DA, Herndon JE, Marcello J, Peters K, Gururangan S, Sathornsumetee S, Rich JN and Friedman HS: Long-term survival from the initial trial of bevacizumab and irinotecan [abstract]. J Clin Oncol 28(15 suppl): 191s, 2010.
86. Friedman HS, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28): 4733-4740, 2009.
87. Cloughesy T, Vredenburgh JJ, Day B, Das A, Friedman HS, the BRAIN Investigators: Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN stud [abstract]. J Clin Oncol 28(15 suppl): 181s, 2010.
88. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P and Gruber ML: Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impal on local control and patient survival. J Neurosurg 110(1): 173-180, 2009.
89. Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M and Lassen U: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 48(1): 52-58, 2009.
90. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy, safety and patterns of response and recurrence inpatients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91(3): 329-336, 2009.
91. Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, van Furth WR and Richel DJ: Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 21(8): 1723-1727, 2010.
92. Thompson EM, Dosa E, Kraemer DF and Neuwelt EA: Bevacizumab plus carboplatin increases survival in patients with recurrent malignit glioma [abstract]. Neuro Oncol 11 (5): 625-626, 2009.
93. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS and Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5): 740-745, 2009.
94. Avastin® [package insert]. South San Francisco, CA: Genentech, Inc, 2009.
95. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M and Nabors LB: Randomized phase II study of cilengitide, an integrin-targeting arginineglycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34): 5610-5617, 2008.
96. Fink K, Mikkelsen T, Nabors LB, Ravin P, Plotkin SR, Schiff D, Hicking C, Picard M and Reardon DA: Long-term effects of cilengitide, a novel integrit inhibitor, in recurrent glioblastoma: A randomized phase IIa study [abstract]. J Clin Oncol 28(15 suppl): 182s, 2010.
97. De Groot JF, Wen PY, Lamborn K, Chang S, Cloughesy TF, Chen AP, DeAngelis LM, Mehta MP, Gilbert MR, Yung WK and Prados MD: Phase II single arm trial of aflibercept in patients with recurrent temozolomideresistant glioblastoma: NABTC 0601 [abstract]. J Clin Oncol 26(15 suppl): 94s, 2008.
98. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN and Yung WK: VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10: 940-945, 2008.
99. Wen PY, Prados M, Schiff D, Reardon DA, Cloughesy T, Mikkelsen T, Batchelor T, Drappatz J, Chamberlain MC and De Groot JF: Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB) [abstract]. J Clin Oncol 28(15 suppl): 181s, 2010.
100. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY and Jain RK: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95, 2007.
101. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT and Sorensen G: Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 12: 466-472, 2010.
102. Miletic H, Niclou SP, Johansson M and Bjervig R: Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets 13: 455-468, 2009.
103. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT and Sorensen G: Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 12(5): 466-472, 2010.
104. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y and Conrad CA: Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12(3): 233-242, 2010.
105. Gruber ML, Kunnakkat S, Medabalmi P, Gruber DB, Golfinos J, Parker E and Narayana A: Change in pattern of relapse in newly diagnosed high-grade glioma following bevacizumab therapy [abstract]. J Clin Oncol 28(15 suppl): 184s, 2010.
106. Platten M, Dörner N, Hofer S, Schäfer N, Schemmer D, Weller M, Bendszus M, Wick W and Wick A: Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignit gliomas: a matched-pair study [abstract]. J Clin Oncol 28(15 suppl): 195s, 2010.
107. Pope WB, Xia Q, Das A, Hambleton J, Kim H, Brown M, Goldin J and Cloughesy TF: Patterns of progression in patients with glioblastoma at first or second relapse treated with bevacizumab alone or in combination with irinotecan in the BRAIN study [abstract]. Neuro Oncol 11(5): 626, 2009.
108. Chamberlain M: Radiographic patterns of relapse in glioblastoma [abstract]. J Clin Oncol 28(15 suppl): 185s, 2010.
109. Chamberlain MC: Radiographic patterns of relapse in glioblastoma. J Neurooncol 101(2): 319-323, 2011.
110. Narayana A, Golfinos JG, Fischer I, Raza S, Kelly P, Parker E, Knopp EA, Medabalmi P, Zagzag D, Eagan P and Gruber ML: Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72(2): 383-389, 2008.
111. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Herndon JE, Marcello J, Bailey L, Threatt S and Friedman HS: Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 28(15 suppl): 185s, 2010.
112. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M and Weller M: Phase I/IIa trial of cilengitide and temozolomide with concomitant radiotherapy, followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16): 2712-2718, 2010.
113. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A and Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
114. Kantoff PW, Higano CS, Shore ND, Berger ER and Small EJ: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.
115. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD and Heimberger AB: Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13: 324-333, 2011.
116. Lai RK, Recht LD, Reardon DA, Paleologos N, Groves M, Myrna RR, Davis T, Green J, Heimberger A and Sampson J: Long-term follow-up of ACT III: A Phase II trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma. Abstract IM-03. Neuro Oncol 13(Suppl 4): iii34-iii40, 2011.
117. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H and Yoshimine T: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108: 963-971, 2008.
118. Parsa AT, Crane C and Han S: A Phase 2 Multicenter Trial of Autologous Heat Shock Protein Peptide Vaccine (HSPPC-96; vitespen) for Recurrent Glioblastoma Multiforme Patients Shows Improved Survival Compared to a Contemporary Cohort Controlled for Age, KPS and Extent of Resection. Annual Scientific Meeting of the American Association of Neurological Surgeons. Abstract 704, 2012.
119. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth- Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E and Van Gool SW: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14: 3098-3104, 2008.
120. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F and De Vleeschouwer S: Integration of autologous dendritic cell-based immunotherapy in the primary
121. Long-term follow-up of DCVax®-treated brain cancer patients shows 33% of patients reached 4-year survival and 27% have reached or exceeded 6-year survival [press release]. Bethesda, MD: Northwest Biotherapeutics, Inc, 2010.
122. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE 2nd, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS and Bigner DD: An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8: 2773-2779, 2009.